Stroke Study Reveals a Key Target For Improving... (ic brain scansand tPA treatment. If t...)

Stroke Study Reveals a Key Target For Improving Treatment

Date:6/22/2008

ic brain scans and tPA treatment.

If the clinical trial in human patients in Sweden bears out the findings seen in mice, perhaps Gleevec could be given immediately upon suspicion of stroke-like symptoms, before diagnostic scans and other tests can be made to determine if a patient could benefit from tPA.

Funding for the study came from the National Institutes of Health, Ludwig Institute for Cancer Research, Karolinska Institutet, the Novo Nordisk Foundation, the Swedish Research Council, the Swedish Cancer Foundation, the LeDucq Foundation and the IngaBritt and Arne Lundberg Foundation.

The study's authors include Linda Fredriksson, Melissa Geyer, Erika Folestad, Jacqueline Cale, Johanna Andrae, Yamei Gao, Kristian Pietras, Kris Mann, Manuel Yepes, Dudley K Strickland, and Christer Betsholtz. Reference: Nature Medicine, DOI 10.1038/nm1787

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Kara Gavin

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=6034

SOURCE University of Michigan Health System
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
2. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
3. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
4. FASgen Announces New Discovery for Treatment of Stroke
5. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. PRoFESS(R) Results Announced at XVII European Stroke Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

Post Your Comments:

(Date:11/24/2009)...MAC,Md.,Nov.24/PRNewswire/--Inadditiontofamily,fri...hiladelphiajurorstoherThanksgivinggratitudelist. ,...hankfultothem,"shesaidofMonday,sverdictstotaling$1..., Wisneskiisamong12,000womennationwidewhohavesued...erapydrugsPremarinandPrempro.Wisneskiandtheothervi...

(Date:11/24/2009)...IEGO,Nov.24/PRNewswire/--Accumetrics,Inc.,aprivate...tem,thefirstrapidandeasy-to-usediagnosticsystemfor...letagents(e.g.Plavix®andaspirin),announcedtod...andGregoryJ.Tibbitts,ChiefFinancialOfficerofAccume...nnualPiperJaffrayHealthCareConferencebeingheldinNe...

(Date:11/24/2009)...IGH,N.C.,Nov.24/PRNewswire/--PharmaceuticalInstitu...orthepharmaceuticalandbiotechindustry,todayannounc...ce .Thenew HospitalMarketplace e-courseisthenewest...) series,acomprehensiveseriesofe-coursesdesignedto...tsknowledgeforcommercialprofessionals. ,, Thene...

Breaking Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2 Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2 Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2 Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 1 Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 2 Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 3 Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance 28TM 29 for Treatment of Acute Pain and Fever 51749 4 Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 1 Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 2 Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 3 Physician Hospitals 28PHA 29 Responds to TIME Magazine Article 3A Filled With Incorrect Assumption and Innuendo 51747 4 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 1 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 2 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 3 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 4 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 5 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 6 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 7 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 8 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 9 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 10 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 11 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 12 China Biotics Inc Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13036 13

[0] Maryland Woman Thankful for Wyeth Verdicts [0] Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference [0] Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace

...1 On December 11, 2008, the Joint Advisory Commit...) - including the Drug Safety & Risk Managemen...ttee, and the Pulmonary-Allergy Drugs Advisory Com...sks of asthma medications containing long-acting b...t the benefits of AstraZeneca,s SYMBICORT(R) (bude...

...a, Dec. 11 Intercell AG (VSE: ICLL) today,announc...he U.S. Department of,Health and Human Services (H...USD 12.5 m for Intercell,s Pandemic Influenza prog...fluenza Vaccine Patch System that,includes an immu... an injected,Pandemic Influenza vaccine (manufactu...

Other Medicine Technology:AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2 AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3 AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4 USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS) 2 USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS) 3

AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

(Date:11/25/2009)....,Nov.25/PRNewswire-USNewswire/--Whenmostpeoplehea...actorcanalsogivepatientsthehelptheyneed.TMJstandsf...mandible)contacts/connectswithyourskull(temporalbo...ysfunctionarepainwithchewing,clickingorpoppingofth...tionincluding:headaches,fatigue,sleepdisturbances,...

(Date:11/25/2009)...v.25/PRNewswire/-SentinelleMedicalInc.,aleadingman...oftwarelaunchesasuiteofnewleadingedgeclinicalappli...matthisyear,sRadiologicalSocietyofNorthAmerica(RSN...00,HallA).Theapplicationsleveragetheuniquehighqual...ingcoilsandsupportmultipleimagingmodalitiesformult...

(Date:11/25/2009)...CO,Nov.25/PRNewswire/--TheBayAreaAirQualityManagem...re the Air Alert forThursday,November26...yothersolidfuel,bothindoorsandoutdoors. ,, "Col...omorrow,"saidJackBroadbent,executiveofficeroftheAi...healthoftheirneighborsandfellowcommunitymembersthi...

(Date:11/25/2009)...iscovery that grew out of a collaboration between ...fer hope to the nearly 10 million Americans who su...o known as hardening of the arteries, peripheral a...roblem in which narrowed arteries reduce blood flo...flag for vascular disease, heart attack and stroke...

(Date:11/25/2009)... Evaluation and treatment clinics to resume...ock (Vocus) November 25, 2009 -- Centegra Health S...nd H1N1 vaccine shots at four Centegra Primary Car... of vaccine has arrived. The clinics are at CPC si...y and will be open as follows: , Fro...

Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2 Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3 Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2 Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2 Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3 Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4 Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2 Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3 Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4

[1] TMJ and Chiropractic Care: An Overall Wellness Approach [1] Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology [0] Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 [1] Engineers, doctors at UCLA develop novel material that could help fight arterial disease [0] Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1

...ters has received the first annual Vision Award fo...ted process to dramatically increase the processin...a. , Irvine, CA (Vocus) O... improvement programs by doing just that. LifeMa...

...Prof. Weihong Song, who is also the Jack Brown and... at UBC, found that if Valproic Acid (VPA) is used...it is reversed. , The study, published in the Jou...In doing so, plaque formation is discontinued. Amy...

...ates Multiple Password Problem With,Single Sign-On...linical and Business Appli...System, one of,the largest healthcare systems in A...up and running with single sign-on (SSO),and conte...

...T -- UCB announced,today the company has joined th...ucation Foundation (REF) as a Pinnacle sponsor of ... Rheumatoid Arthritis." The,announcement was made ... disease can be eradicated and this will happen on...

...ious atrial fibrillation, review finds, , ...bone-building medications known as bisphosphonates.... , A review of available research concludes that ... strokes. , "In addition to possible gastrointesti...

...Corporation,(Nasdaq: HLTH ) announced today that ...o 80,000,000 shares of its common stock at a price... to be purchased in the tender offer,represents ap...t on October 24, 2008 was $8.06 per share., The t...

Other Medicine News:Health News:LifeMasters Receives 2008 Vision Award for Business Impact 2 Health News:LifeMasters Receives 2008 Vision Award for Business Impact 3 Health News:Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians 2 Health News:Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians 3 Health News:UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign 2 Health News:UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign 3 Health News:Osteoporosis Meds Linked to Heart Problem 2 Health News:Osteoporosis Meds Linked to Heart Problem 3 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 2 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 3 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 4

LifeMasters Receives 2008 Vision Award for Business Impact Common epilepsy drug could prevent and treat Alzheimer's disease Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign Osteoporosis Meds Linked to Heart Problem HLTH Corporation Announces Commencement of Its Tender Offer

Double LASIK Flap Irrigation Cannula

Sheets-McPherson Tying Forceps

8.0mm Notched Trephine Blades

11.00mm diameter Corneal Trephine Blades

Medicine Products:

Double LASIK Flap Irrigation Cannula Sheets-McPherson Tying Forceps 8.0mm Notched Trephine Blades 11.00mm diameter Corneal Trephine Blades

Stroke Study Reveals a Key Target For Improving...(ic brain scansand tPA treatment. If t...),Health